论文部分内容阅读
目的应用色素原位杂交法(chromogenic in situ hybridization,CISH)检测HER2蛋白弱阳性表达乳腺癌患者的HER2基因扩增状态,为乳腺癌的临床诊治提供依据。方法收集HER2蛋白弱阳性()表达乳腺癌患者石蜡切片标本187例,采用Invitrogen公司的HER2CISHTM检测试剂盒,根据美国临床肿瘤学会/美国病理医师学会推荐标准,分析标本HER2基因状态及其与雌激素受体(ER)、孕激素受体(PR)表达的相关性。结果乳腺癌HER2蛋白弱阳性表达标本HER2基因扩增阳性率为53.48%(100/187),基因扩增阳性者ER、PR阳性表达率分别为44.00%、46.00%;HER2基因扩增阴性率为46.52%(87/187),基因扩增阴性者ER、PR阳性表达率分别为70.73%、78.05%。HER2基因扩增结果与性激素受体(ER、PR)表达明显负相关(P<0.01)。结论 HER2蛋白弱阳性表达乳腺癌患者有必要进一步明确其基因扩增状态,CISH可有效检测此类患者的HER2基因扩增状态。
Objective To detect the amplification status of HER2 gene in HER2-positive breast cancer patients by chromogenic in situ hybridization (CISH), and to provide evidence for the clinical diagnosis and treatment of breast cancer. METHODS: A total of 187 specimens of breast cancer were collected from patients with HER2 protein weakly positive expression (). The HER2CISHTM kit from Invitrogen was used to analyze the HER2 gene status of the specimens and their relationship with the female Hormone receptor (ER), progesterone receptor (PR) expression of the correlation. Results The positive rate of HER2 gene expression in HER2 positive breast cancer specimens was 53.48% (100/187). The positive rates of ER and PR in positive breast cancers were 44.00% and 46.00% respectively. The negative rates of HER2 gene amplification were 46.52% (87/187). The positive rates of ER and PR in negative gene amplification were 70.73% and 78.05% respectively. The result of HER2 gene amplification was negatively correlated with the expression of sex hormone receptor (ER, PR) (P <0.01). Conclusion It is necessary to further clarify the status of gene amplification in breast cancer patients with weak positive expression of HER2 protein. CISH can effectively detect the amplification status of HER2 gene in these patients.